Drug Type Small molecule drug |
Synonyms 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone |
Target |
Mechanism GPER1 agonists(G protein-coupled estrogen receptor 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Linnaeus Therapeutics, Inc.Startup |
Active Organization Linnaeus Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC21H18BrNO3 |
InChIKeyVHSVKVWHYFBIFJ-HKZYLEAXSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma, Cutaneous Malignant | Phase 3 | - | Linnaeus Therapeutics, Inc.Startup | 01 Nov 2024 |
Unresectable Melanoma | Phase 3 | - | Linnaeus Therapeutics, Inc.Startup | 01 Nov 2024 |
Advanced cancer | Phase 2 | US | Linnaeus Therapeutics, Inc.Startup | 21 Oct 2019 |
Solid tumor | Phase 2 | US | Linnaeus Therapeutics, Inc.Startup | 21 Oct 2019 |
Lymphoma | Phase 1 | US | Linnaeus Therapeutics, Inc.Startup | 21 Oct 2019 |
Pancreatic Cancer | Phase 1 | US | Linnaeus Therapeutics, Inc.Startup | 08 Sep 2019 |
Phase 1 | germline GPER | 9 | jfisilhtmn(rqmcdtohsn) = G3 and G1 aqajlkptwh (xmeqwiqvbc ) View more | Positive | 14 Sep 2024 | ||
Phase 1/2 | Refractory Melanoma consensus germline GPER | 10 | LNS8801 + pembrolizumab | itrtczzkyt(ikmlhpmjnd) = jlynsvlkit ekylxcajfc (oriklwoojl ) View more | Positive | 02 Nov 2023 | |
Phase 1/2 | - | LNS8801 (125 mg, QD, PO) + Pembrolizumab (200 mg, Q3W, IV) | (sazlskmlgq) = opvwpgqydp upqbmbkezg (dgyshdtqvk ) View more | - | 22 Oct 2023 | ||
NCT04130516 (ASCO2023) Manual | Phase 1/2 | 15 | (jkoypjbrlp) = 4 of 8 monotherapy patients had AEs potentially related to study drug (all grade 1), with no AEs occurring in more than one patient. 6 of 7 combination patients had AEs potentially related to study drugs (grades 1-2), with fatigue occurring in more than one patient. kuhvoumkfj (xyzufscoix ) | Positive | 31 May 2023 | ||
LNS8801 125 mg+pembrolizumab 200 mg | |||||||
Phase 1/2 | 13 | LNS8801+Pembrolizumab | (nxzydjihkg) = LNS8801 was identified as 125 mg daily as a monotherapy and in combination with pembrolizumab (200 mg every 3 weeks) wwgduznlui (dzybkbmvks ) | Positive | 06 Jun 2022 | ||
NCT04130516 (ASCO2022) Manual | Phase 1 | 13 | LNS8801 125 mg+pembrolizumab 200 mg | (nflfwbwvom) = ounkskrdxr fnxmwlwhjq (babvhqwuai ) View more | Positive | 02 Jun 2022 | |
NCT04130516 (ASCO2021) Manual | Phase 1 | 33 | (tbxlbhqasn) = evjwdagzow wvfhsciyfe (rpgedvxbcw ) View more | Positive | 20 May 2021 | ||
LNS8801+pembrolizumab | (tbxlbhqasn) = qiefzbclei wvfhsciyfe (rpgedvxbcw ) View more |